Avalo Therapeutics AVTX Business Segments — Salaries, benefits and related costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — salaries, benefits and related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — salaries, benefits and related costs?
- Avalo Therapeutics (AVTX) reported business segments — salaries, benefits and related costs of $2.59M in Q1 2026.
- How has Avalo Therapeutics's business segments — salaries, benefits and related costs changed year-over-year?
- Avalo Therapeutics's business segments — salaries, benefits and related costs increased by 39.8% year-over-year, from $1.85M to $2.59M.
- What is the long-term trend for Avalo Therapeutics's business segments — salaries, benefits and related costs?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — salaries, benefits and related costs has grown at a 54.2% compound annual growth rate (CAGR), from $3.58M to $8.5M.
- What does business segments — salaries, benefits and related costs mean?
- Reflects the total personnel-related expenditures, including wages, benefits, and payroll taxes for staff dedicated to the reportable segment. This metric serves as a proxy for the human capital investment required to support the company's research and development operations. Tracking these costs provides insight into the company's organizational growth and operational overhead.